Immune checkpoint therapy, which targets regulatory immune checkpoint pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. Although some adverse effects have been found, immune checkpoint therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. Several clinical trials have since investigated new agents in immune checkpoint therapy, alone and in combination, for various cancers.
Numerous achievements have been gained about immune checkpoint therapy in cancer, based on research of various immune checkpoint molecules
There are at least 3 broad possible ways to approach combination for immune checkpoint therapy in cancer.
In these years, immune checkpoint therapy is striking in cancer therapy with durable responses and long-term survival.
unique adverse effects can occur through nonspecific immunologic activation due to the immune enhancing effects of immune checkpoint therapy in cancer
Michael A. Postow. Immune Checkpoint Blockade in Cancer Therapy. American Society of Clinical Oncology 2015; 33:1974-1982.
Philippe Armand. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125:22.
Padmanee Sharma et al. The future of immune checkpoint therapy. Science 2015; 348:56-61.